ArticleJournal of ginseng research2021
Effects of red ginseng on gut, microbiota, and brain in a mouse model of post-infectious irritable bowel syndrome.
Article in Journal of ginseng research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Review
- Using Plant-Derived Polysaccharides in the Management of Cognitive Disorders: Molecular and Clinical Perspectives.Nutrients · 2026Review
- Therapeutic potential of ginseng and its bioactive compounds in inflammatory bowel disease: current evidence and future directions.Frontiers in immunology · 2026Review
- Synergistic Modulation of the Gut-Brain-Immune Axis by a DualJournal of microbiology and biotechnology · 2025Article
- Plant-Derived Nutraceuticals in Mental Health and Brain Function: Mechanisms of Action and Therapeutic Potential.International journal of molecular sciences · 2025Review
- Effects of red ginseng extract and red ginseng dietary fiber on the maintenance of intestinal immune and functional homeostasis in diet-induced obese mice.Journal of ginseng research · 2025Article
- Lacidophilin tablets relieve irritable bowel syndrome in rats by regulating gut microbiota dysbiosis and intestinal inflammation.Scientific reports · 2025Article
- Therapeutic potential of the gut commensal bacteriumFrontiers in microbiology · 2025Review
- Ginseng as a therapeutic target to alleviate gut and brain diseases via microbiome regulation.Journal of ginseng research · 2025Review
- The beneficial potential of ginseng for menopause.Journal of ginseng research · 2024Review
- Article
- Brain plasticity and ginseng.Journal of ginseng research · 2024Review
- Pharmacological effects of ginseng and ginsenosides on intestinal inflammation and the immune system.Frontiers in immunology · 2024Review
- Treatment of Chronic Gastritis with Traditional Chinese Medicine: Pharmacological Activities and Mechanisms.Pharmaceuticals (Basel, Switzerland) · 2023Review
- KRG and its major ginsenosides do not show distinct steroidogenic activities examined by the OECD test guideline 440 and 456 assays.Journal of ginseng research · 2023Article
- The interaction between ginseng and gut microbiota.Frontiers in nutrition · 2023Review
- Suppression of PTRF Alleviates Post-Infectious Irritable Bowel Syndrome via Downregulation of the TLR4 Pathway in Rats.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIrritable bowel syndrome (IBS), the most common functional gastrointestinal disorder, is characterized by chronic abdominal pain and bowel habit changes. Although diverse complicated etiologies are involved in its pathogenesis, a dysregulated gut-brain axis may be an important factor. Red ginseng (RG), a traditional herbal medicine, is proven to have anti-inflammatory effects and improve brain function; however, these effects have not been investigated in IBS.
methodsThree-day intracolonic zymosan injections were used to induce post-infectious human IBS-like symptoms in mice. The animals were randomized to receive either phosphate-buffered saline (CG) or RG (30/100/300 mg/kg) for 10 days. Amitriptyline and sulfasalazine were used as positive controls. Macroscopic scoring was performed on day 4. Visceral pain and anxiety-like behaviors were assessed by colorectal distension and elevated plus maze and open field tests, respectively, on day 10. Next-generation sequencing of gut microbiota was performed, and biomarkers involved in gut-brain axis responses were analyzed.
resultsCompared to CG, RG significantly decreased the macroscopic score, frequency of visceral pain, and anxiety-like behavior in the IBS mice. These effects were comparable to those after sulfasalazine and amitriptyline treatments. Moreover, RG significantly increased the proliferation of beneficial microbes, including
conclusionRG may be a potential therapeutic option for the management of human IBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.